KPIs & Operating Metrics(New)
Breakdown Of AssetsCost Of SalesEmployee StatisticsGross Margin %Gross Margin Annual %Gross ProfitGross Profit AnnualIncome Before Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant And Equipment BreakdownRevenue By Business SegmentRevenue By Business Segment %Revenue By Business Segment AnnualRevenue By Business Segment Annual %Revenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By Product BiosimilarsRevenue By Product (Biosimilars) AnnualRevenue By Product CardiovascularRevenue By Product (Cardiovascular) AnnualRevenue By Product Non Opid Pain , Bone & DermatologyRevenue By Product (Non Opid Pain , Bone & Dermatology) AnnualRevenue By Product RespiratoryRevenue By Product (Respiratory) AnnualRevenue By Product Women'S HealthRevenue By Product (Women'S Health) Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares Outstanding
Ratios

Organon (OGN) Gross Profit (2020 - 2025)

Organon has reported Gross Profit over the past 7 years, most recently at $783.0 million for Q1 2026.

  • For Q1 2026, Gross Profit fell 6.9% year-over-year to $783.0 million; the TTM value through Mar 2026 reached $3.3 billion, down 9.56%, while the annual FY2025 figure was $3.3 billion, 10.82% down from the prior year.
  • Gross Profit for Q1 2026 was $783.0 million at Organon, up from $741.0 million in the prior quarter.
  • Over five years, Gross Profit peaked at $1.0 billion in Q1 2022 and troughed at $741.0 million in Q4 2025.
  • A 5-year average of $908.2 million and a median of $915.0 million in 2023 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: grew 9.95% in 2022 and later dropped 17.3% in 2025.
  • Year by year, Gross Profit stood at $891.0 million in 2022, then rose by 2.69% to $915.0 million in 2023, then dropped by 2.08% to $896.0 million in 2024, then dropped by 17.3% to $741.0 million in 2025, then rose by 5.67% to $783.0 million in 2026.
  • Business Quant data shows Gross Profit for OGN at $783.0 million in Q1 2026, $741.0 million in Q4 2025, and $857.0 million in Q3 2025.